Leading in the Age of Evidence, genomic diagnostic products #Afirma #Percepta #Envisia #thyroidcancer #lungcancer #IPF
Location: United States, California, South San Francisco
Employees: 501-1000
Total raised: $101M
Founded date: 2008
Investors 3
| Date | Name | Website |
| - | Domain Ass... | domainvc.c... |
| - | Kleiner Pe... | kleinerper... |
| - | TPG | tpg.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 28.03.2016 | - | $45M | - |
| 01.07.2013 | Series C | $28M | - |
| 10.06.2010 | Series B | $28M | - |
Mentions in press and media 14
| Date | Title | Description |
| 12.01.2026 | Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team | T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors FREMONT, Calif., ... |
| 08.01.2024 | Veracyte Acquires C2i Genomics | Veracyte, Inc. (Nasdaq: VCYT), a South San Francisco, CA-based cancer diagnostics company, reached a definitive agreement to acquire C2i Genomics, Inc. a Haifa, Israel-based minimal residual disease (MRD) detection company. Under the terms ... |
| 05.12.2022 | A Tumor Microenvironment-Based Multiomics Analysis for Predictive Modelling: Upcoming Webinar Hosted by Xtalks | With a growing number of clinical trials testing immune checkpoint inhibitors (ICI) or CAR T therapies, one of the main objectives for researchers now is to extend immunotherapeutic approaches to more patients and tumor types while decreasi... |
| 09.06.2022 | Improving Clinical Research in Oncology Using Immune Scoring Biomarkers & a Multi-omics Approach, Upcoming Webinar Hosted by Xtalks | In this promising race against cancer, biomarkers represent one of the cornerstones of drug development programs and can be used in clinical trials to select patients and, ultimately, be employed as companion diagnostics. TORONTO (PRWEB) Ju... |
| 09.07.2021 | Veracyte Announces Key Appointments To Executive Leadership Team, Supporting Global Expansion | Rob Brainin Named Executive Vice President and Chief Business Officer; Bill Zondler Appointed Senior Vice President and Chief Information Officer Veracyte, Inc. a global genomic diagnostics company, announced key appointments that further s... |
| 22.03.2021 | Veracyte Appoints Muna Bhanji to Its Board of Directors | SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar 22, 2021-- Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, today announced the appointment of Muna Bhanji, R.Ph., a global senior healthcare executive, to its board of d... |
| 15.03.2021 | Veracyte Completes Acquisition of Decipher Biosciences | SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar 15, 2021-- Veracyte, Inc. (Nasdaq: VCYT) today announced it has completed its acquisition of Decipher Biosciences, Inc. to further solidify its global leadership in genomic diagnostics, with... |
| 10.03.2021 | Veracyte Commends New USPSTF Lung Cancer Screening Guidelines | SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar 10, 2021-- Veracyte, Inc. (Nasdaq: VCYT) today commended the U.S. Preventive Services Task Force (USPSTF) for its new, revised recommendations that expand eligibility for lung cancer screeni... |
| 28.03.2016 | Veracyte nabs $45M from Visium Healthcare Partners to further grow molecular diagnostics business | The next step for the company is to focus on its Percepta Bronchial Genomic Classifier – this was picked up back in 2014 when it brought in $21 million in a deal with Allegro Diagnostics. This test allows doctors to look at 23 genes in cell... |
| 30.10.2013 | Domain, Versant Portfolio Firm Veracyte Hits IPO Market | Southern California venture capital investors Domain Associates and Versant Venture saw a public exit of one of their portfolio companies this morning, molecular diagnostics equipment maker Veracyte. Veracyte debuted on the NASDAQ Global Ma... |
Show more